Wechselwirkungen · Lynkuet
Lynkuet 60 mg soft capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-152493 · Präparat HOS-100773
CYP3A4 inhibitors (substances increasing exposure to elinzanetant) Co-administration of multiple daily doses of itraconazole (200 mg), a strong CYP3A4 and P-gp inhibitor, and elinzanetant 120 mg resulted in an increase of approximately 3.3-fold in Cmax and between 4.6-fold and 6.3-fold in area under the curve (AUC) of elinzanetant. Physiologically based pharmacokinetic (PBPK) modelling predictions after co-administration of 120 mg elinzanetant with the moderate CYP3A4 inhibitor erythromycin showed a 3-fold increase of AUC and 2-fold increase for Cmax of elinzanetant. PBPK predictions after co-administration of 60 mg elinzanetant with the moderate CYP3A4 inhibitor erythromycin showed a 1.4-fold increase of AUC and no increase in Cmax compared to 120 mg elinzanetant alone. PBPK predictions after co-administration of 120 mg elinzanetant with the weak CYP3A4 inhibitor cimetidine showed a 1.5-fold increase of AUC and 1.3-fold increase for Cmax of elinzanetant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) itraconazole (HOS-084516) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T16:50:00Z · SHA-256 ecbf0f6b79f1c6bfe216be12964b8f103c624e0a839ceaf53734fa83bdbafefa · Passage 6ff72d8565f0a3da73584f6e2e0056ed749267a0c622d90246866e72954af232 · Zeichen 163–1132 im Abschnitt